Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy

A. Young Cho, Hyun Ju Yoon, Kwang Young Lee and In O. Sun

Department of Internal Medicine, Division of Nephrology, Presbyterian Medical Center, Jeonju, Korea

ABSTRACT

Objective: The aim of this study was to investigate the clinical characteristics of sepsis-induced acute kidney injury (AKI) in patients undergoing continuous renal replacement therapy (CRRT).

Methods: From 2011 to 2015, we enrolled 340 patients who were treated with CRRT for sepsis at the Presbyterian Medical Center. In all patients, CRRT was performed using the PRISMA platform. We divided these patients into two groups (survivors and non-survivors) according to the 28-day all-cause mortality. We compared clinical characteristics and analyzed the predictors of mortality.

Results: The 28-day all-cause mortality was 62%. Survivors were younger than non-survivors and had higher platelet counts (178 ± 101 × 10^3/mL vs. 134 ± 84 × 10^3/mL, \( p < .01 \)) and serum creatinine levels (4.2 ± 2.8 vs. 3.3 ± 2.7, \( p < .01 \)) than non-survivors. However, survivors had lower red blood cell distribution width (RDW) scores (14.9 ± 2.1 vs. 16.1 ± 3.3, \( p < .01 \)) and APACHE II scores (24.5 ± 5.8 vs. 26.9 ± 5.7, \( p < .01 \)) than non-survivors. Furthermore, survivors were more likely than non-survivors to have a urine output of >0.05 mL/kg/h (66% vs. 86%, \( p = .001 \)) in the first day. In a multivariate logistic regression analysis, age, platelet count, RDW score, APACHE II score, serum creatinine level, and a urine output of <0.05 mL/kg/h the first day were prognostic factors for the 28-day all-cause mortality.

Conclusion: Age, platelet count, APACHE II score, RDW score, serum creatinine level, and urine output the first day are useful predictors for the 28-day all-cause mortality in sepsis patients requiring CRRT.

ARTICLE HISTORY

Received 6 January 2018
Revised 12 March 2018
Accepted 7 June 2018

KEYWORDS

Acute kidney injury; continuous renal replacement therapy; sepsis; platelet; urine output

Introduction

Acute kidney injury (AKI) is a common and serious complication in critically ill patients, and the development of AKI increases morbidity and mortality in these patients [1–4]. Sepsis is the leading cause of AKI treated with renal replacement therapy (RRT) in critically ill patients. The overall incidence of sepsis-induced AKI among all intensive care unit (ICU) admissions typically ranges between 15 and 20% [5].

Continuous renal replacement therapy (CRRT) is the established treatment modality in critically ill patients with AKI in the ICU [6]. Several predictors of survival in patients on CRRT have been described based on cross-sectional and retrospective studies [7–9]. It has been reported that sepsis-induced AKI is distinct from AKI in its pathophysiology without sepsis [10–12]. Therefore, sepsis-induced AKI may be distinguished from non-septic AKI in patient characteristics and clinical outcomes. Septic AKI patients have a poor prognosis compared to non-septic patients [13]. However, there have been few studies about the prognostic factors predicting mortality in patients with sepsis-induced AKI undergoing CRRT. Therefore, we investigated the clinical characteristics of sepsis-induced AKI patients undergoing CRRT and evaluated the predictors of mortality.

Methods

Patient selection

From 2011 to 2015, all 340 enrolled patients were ≥18 years, suffered from sepsis and AKI in the Presbyterian Medical Center ICU, required CRRT, and met at least one of the following criteria: oliguria (urine output <100 mL in a 6-h period and unresponsive to
Clinical and laboratory information

All patients underwent detailed clinical history-taking, an examination, and a standard set of investigations including complete blood count, chest radiograph, urinalysis, two blood cultures, and tests for liver function, serum creatinine, urea, and electrolytes. The AKI was defined according to the Kidney Disease: Improving Global Outcome (KDIGO) guidelines [15]. Acute Physiology and Chronic Health Evaluation (APACHE) II and Sepsis-related organ failure assessment (SOFA) scores for all patients were obtained at the initial time of CRRT. The reference range for red blood cell distribution width (RDW) levels in this study was 12.2–14.8%. The patients’ weights were obtained in a variety of settings: the emergency room, nursing floor, and the ICU. Standard hospital scales were used for ambulatory patients and bed scales for non-ambulatory or ICU patients. The first available documented weight on the hospital record was taken as the initial weight, the majority of which were in the ICU. Subsequent daily weight was monitored with bed scales by the nursing staff and recoded on the care flow sheets. In all patients, continuous venovenous hemodiafiltration (CVVHDF) was performed using the PRISMA platform (Gambro, Hechingen, Germany). The CRRT prescriptions are shown in Table 1. Recovery of renal function was classified as complete when eGFR was within 25% of the reference eGFR (based on reference serum creatinine). Incomplete kidney recovery was defined as patients who had a 25% or greater decline of reference eGFR.

Statistical analysis

All data are presented as means ± standard deviations unless otherwise specified. The baseline characteristics of patients in the survivor and non-survivor groups were compared using t-tests, chi-square tests, or Fisher’s exact tests, as appropriate. A multiple logistic regression analysis was applied to predict the 28-day all-cause mortality after starting CRRT. A p-value of < .05 was considered to be statistically significant. All statistical analyses were carried out using SPSS version 22.0 (SPSS Inc., Chicago, IL).

Results

Baseline characteristics

The baseline characteristics of the 340 study subjects are presented in Table 2. The patients included 214 (63%) men and 126 (37%) women, with a mean age of 67 years (range, 21–92). The initial hemoglobin and mean RDW levels were 10.4 g/dL and 15.7%, respectively. The mean creatinine level at the start of CRRT was 3.6 mg/dL, and the mean APACHE II score was 26.0 (range, 7–42). The mean platelet count was 178 × 10^3/mL. The most common cause of sepsis was pneumonia.
Table 2. The clinical and laboratory findings of the 340 patients with sepsis-induced AKI undergoing CRRT.

| Characteristics | Value |
|-----------------|-------|
| Age, years      | 68 ± 13 |
| Male, n (%)     | 214 (63) |
| Sepsis status   |       |
| Sepsis, n (%)   | 10 (3.0) |
| Severe sepsis, n (%) | 89 (26.3) |
| Septic shock, n (%) | 241 (70.7) |
| Cause of sepsis |       |
| Thoracic, n (%) | 205 (60.3) |
| Intra-abdominal, n (%) | 45 (13.2) |
| Urogenital, n (%) | 34 (10) |
| Skin/soft tissue/bone, n (%) | 11 (3.2) |
| Other, n (%)    | 19 (5.6) |
| Source unknown, n (%) | 26 (7.7) |
| Indication of CRRT |       |
| Oliguria, n (%) | 37 (10.9) |
| Hyperkalemia, n (%) | 10 (2.9) |
| Acidemia, n (%) | 31 (9.1) |
| Organ edema, n (%) | 41 (12.1) |
| Mixed, n (%)    | 221 (65) |
| Comorbidity, n (%) |       |
| Diabetes, n (%) | 157 (46) |
| Hypertension, n (%) | 225 (66) |
| Congestive heart failure, n (%) | 77 (23) |
| Liver cirrhosis, n (%) | 47 (14) |
| Chronic kidney disease, n (%) | 114 (33) |
| Ischemic heart disease, n (%) | 108 (32) |
| Systolic blood pressure (mmHg) | 82 ± 23 |
| Diastolic blood pressure (mmHg) | 51 ± 14 |
| APACHE score    | 26.0 ± 5.9 |
| SOFA score      | 11.7 ± 3.2 |
| RBC transfusion, unit | 2.8 ± 4.1 |
| Hemoglobin (mg/dL) | 10.4 ± 2.4 |
| Serum creatinine (mg/dL) | 3.6 ± 2.8 |
| Total bilirubin (mg/dL) | 2.1 ± 5.0 |
| Serum albumin (mg/dL) | 2.9 ± 0.6 |
| WBC count (× 10^9/L) | 15.1 ± 9.2 |
| C-reactive protein (mg/dL) | 11.5 ± 11.0 |
| RDW (%)         | 15.7 ± 2.9 |
| Electrolyte     |       |
| Na (mmol/L)     | 137 ± 10 |
| K (mmol/L)      | 4.4 ± 1.5 |
| Cl (mmol/L)     | 101 ± 8 |
| Ca (mg/dL)      | 7.9 ± 0.9 |
| P (mg/dL)       | 5.0 ± 2.8 |
| Mg (mmol/L)     | 2.4 ± 0.6 |
| ABGA            |       |
| pH              | 7.28 ± 0.16 |
| PaO2 (mmHg)     | 97.4 ± 49.7 |
| PaCO2 (mmHg)    | 33.5 ± 13.0 |
| HCO3 (mmol/L)   | 14.6 ± 6.8 |
| Lactic acid levela (mmol/L) | 7.6 ± 7.2 |
| Platelet count (× 10^9/L) | 150 ± 93 |
| UO <0.5 mL/kg/h during D1, n (%) | 266 (78) |
| Renal outcome   |       |
| Complete recovery, n (%) | 84 (66) |
| Incomplete recovery, n (%) | 28 (22) |
| Dialysis dependence, n (%) | 16 (12) |
| Death, n (%)    | 212 (62) |

APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: sepsis-related organ failure; RBC: red blood cell; WBC: white blood cell; RDW: red blood cell distribution width; UO: urine output; ABGA: arterial blood gas analysis.
aLactic acid level was available in 255 patients.

Comparison of clinical characteristics between survivors and non-survivors

When we compared clinical characteristics between survivors (n = 212) and non-survivors (n = 128), the survivors were younger than non-survivors (64 ± 14 years vs. 69 ± 12 years, p < .01) and had higher serum creatinine levels (4.2 ± 2.8 vs. 3.3 ± 2.7, p < .01) and platelet counts (178 ± 101 vs. 134 ± 84, p < .01). However, survivors had lower RDW values (14.9 ± 2.1 vs. 16.1 ± 3.3, p < .01) and lower APACHE II scores (24.5 ± 5.8 vs. 26.9 ± 5.7, p < .01) than non-survivors. Survivors were more likely than non-survivors (82% vs. 66%, p < .01) to have a urine output of >0.05 mL/kg/h (66% vs. 86%, p = .001) during the first day. Non-survivors had more liver cirrhosis (18% vs. 7%, p = .003) and lower serum albumin levels (2.8 ± 0.6 vs. 3.0 ± 0.7, p < .01) than survivors (Table 3).

Predicting survival in septic AKI patients undergoing CRRT

A univariate analysis indicated that age, serum albumin level, RDW value, APACHE II score, platelet count, serum creatinine level, presence of liver cirrhosis, and urine output <0.05 mL/kg/h the first day were significant predictors of mortality in sepsis-induced AKI patients undergoing CRRT. After adjusting for these factors in a multivariate logistic regression analysis, age, APACHE II score, RDW value, platelet count, serum creatinine level, and a urine output <0.05 mL/kg/h the first day were prognostic factors for the 28-day all-cause mortality in sepsis patients needing CRRT (Table 4).

Discussion

Sepsis is a major unresolved medical challenge. It is the leading cause of AKI and contributes to multiple organ dysfunction syndrome, a very serious medical condition [5,16]. The CRRT is an important treatment modality for sepsis because it can extract or lower the concentrations of many pro-inflammatory mediators, and therefore has immunomodulatory effects [6,17,18]. Patients with septic AKI have an increased risk for death and a longer average duration of hospitalization [13]. In patients with sepsis-induced AKI undergoing CRRT, the 28-day mortality ranged from 38% to 66% in previous reports [19–22]. The mortality was 62% in our study, comparable to previous reports. This finding might be explained by the similar APACHE II scores (which reflect a patient’s severity) in this and the previous studies.

Most previous studies on CRRT have included both septic and non-septic AKI patients, whereas only septic AKI patients were included in the present study. Age,
Table 3. Comparison of baseline characteristics between survivors and non-survivors.

| Variable                                  | Survivor (n = 128) | Non-survivor (n = 212) | p-value |
|-------------------------------------------|--------------------|------------------------|---------|
| Age                                       | 64 ± 14            | 69 ± 12                | .001    |
| Male, n (%)                               | 79 (40)            | 135 (63)               | NS      |
| Sepsis status                             |                    |                        |         |
| Sepsis, n (%)                             | 5                  | 5                      | NS      |
| Severe sepsis, n (%)                      | 40                 | 49                     | NS      |
| Septic shock, n (%)                       | 71                 | 170                    | <.001   |
| Cause of sepsis                           |                    |                        |         |
| Thoracic, n (%)                           | 98 (48)            | 107 (52)               | NS      |
| Intra-abdominal, n (%)                    | 21 (47)            | 24 (53)                | NS      |
| Urogenital, n (%)                         | 14 (41)            | 20 (59)                | NS      |
| Skin/soft tissue/bone, n (%)              | 6 (55)             | 5 (45)                 | NS      |
| Other, n (%)                              | 11 (58)            | 8 (42)                 | NS      |
| Source unknown, n (%)                     | 11 (42)            | 15 (58)                | NS      |
| Indication of CRRT                        |                    |                        |         |
| Oliguria, n (%)                           | 17 (46)            | 20 (54)                | NS      |
| Hyperkalemia, n (%)                       | 4 (40)             | 6 (60)                 | NS      |
| Acidemia, n (%)                           | 13 (32)            | 18 (68)                | NS      |
| Organ edema, n (%)                        | 16 (39)            | 25 (61)                | NS      |
| Mixed, n (%)                              | 99 (45)            | 122 (55)               | NS      |
| Comorbidity                               |                    |                        |         |
| Diabetes, n (%)                           | 63 (49)            | 94 (44)                | NS      |
| Hypertension, n (%)                       | 90 (70)            | 135 (64)               | NS      |
| Congestive heart failure, n (%)           | 26 (21)            | 51 (24)                | NS      |
| Liver cirrhosis, n (%)                    | 9 (7)              | 38 (18)                | .003    |
| Chronic kidney disease, n (%)             | 47 (41)            | 67 (59)                | NS      |
| Ischemic heart disease, n (%)             | 37 (34)            | 71 (66)                | NS      |
| Systolic blood pressure (mmHg)            | 86 ± 25            | 79 ± 21                | .003    |
| Diastolic blood pressure (mmHg)           | 52 ± 14            | 49 ± 13                | NS      |
| APACHE 2 score                            | 24.5 ± 5.8         | 26.9 ± 5.7             | <.001   |
| SOFA score                                | 10.3 ± 3.1         | 12.5 ± 2.9             | <.001   |
| RBC transfusion                           | 2.7 ± 3.2          | 2.9 ± 4.6              | NS      |
| Hemoglobin (mg/dL)                        | 10.3 ± 2.4         | 10.4 ± 2.4             | NS      |
| Serum creatinine (mg/dL)                  | 4.2 ± 2.8          | 3.3 ± 2.7              | .007    |
| Total bilirubin (mg/dL)                   | 1.0 ± 1.4          | 2.7 ± 6.1              | .002    |
| Serum albumin (mg/dL)                     | 3.0 ± 0.7          | 2.8 ± 0.6              | .001    |
| WBC count (× 10³/µL)                      | 15.3 ± 8.9         | 14.9 ± 9.2             | NS      |
| C-reactive protein (mg/dL)                | 11.6 ± 11.0        | 11.3 ± 11.2            | NS      |
| RDW (%)                                   | 14.9 ± 2.1         | 16.1 ± 3.3             | <.001   |
| Electrolyte                               |                    |                        |         |
| Na (mmol/L)                               | 136 ± 14           | 138 ± 6                | NS      |
| K (mmol/L)                                | 4.5 ± 2.1          | 4.3 ± 0.9              | NS      |
| Cl (mmol/L)                               | 101 ± 9            | 101 ± 7                | NS      |
| Ca (mg/dl)                                | 7.8 ± 1.0          | 8.0 ± 0.9              | NS      |
| P (mg/dl)                                 | 5.1 ± 3.1          | 5.0 ± 2.5              | NS      |
| Mg (mmol/L)                               | 2.4 ± 0.7          | 2.4 ± 0.6              | NS      |
| ABGA                                      |                    |                        |         |
| pH                                        | 7.29 ± 0.14        | 7.27 ± 0.16            | NS      |
| PaO2 (mmHg)                               | 97.7 ± 10.9        | 97.2 ± 56.2            | NS      |
| PaCO2 (mmHg)                              | 32.2 ± 12.7        | 34.2 ± 13.1            | NS      |
| HCO3 (mmol/L)                             | 14.2 ± 6.8         | 14.8 ± 6.8             | NS      |
| Lactic acid level* (mmol/L)               | 7.0 ± 7.6          | 7.9 ± 7.0              | NS      |
| Platelet count (× 10³/µL)                 | 178 ± 101          | 134 ± 84               | <.001   |
| UO < 0.5 ml/kg/h during D1, n (%)         | 84 (66)            | 182 (86)               | .001    |

APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: sepsis-related organ failure; RBC: red blood cell; WBC: white blood cell; RDW: red blood cell distribution width; UO: urine output; ABGA: arterial blood gas analysis.

*Lactic acid level was available in 255 patients.

elevated RDW value is a predictor of morbidity and mortality in cardiovascular diseases [25,26]. Recently, it was reported that a high RDW value is also associated with mortality in older patients with sepsis and in patients treated with CRRT [27,28]. Our study revealed that the RDW score can be a prognostic factor predicting mortality in sepsis-induced AKI patients undergoing CRRT. Although the mechanism underlying the association between higher RDW and adverse outcome in patients with sepsis is not completely understood, several mechanisms can be postulated. First, systemic inflammation response in sepsis inhibits erythrocyte maturation and accelerates the migration of reticulocytes into the peripheral circulation, thereby increasing RDW [29]. Second, high oxidative stress in sepsis, which is present through the generation of reactive oxygen species by activated leukocytes, induces an increasing RDW by reducing red blood cell (RBC) survival and increasing the release of large premature RBCs into the peripheral circulation [30,31]. In addition, the release of cytokine in response to inflammatory stress might block the activity of erythropoietin and inhibit erythrocyte maturation and cause production of ineffective red blood cell and elevated RDW [32]. To our knowledge, this is the first report to show an association between RDW and mortality in patients with sepsis-induced AKI undergoing CRRT. Therefore, when starting CRRT for sepsis-induced AKI patients with a high RDW score, it may be necessary to treat aggressively and carefully.

The APACHE II score is a prognostic factor in both sepsis and AKI patients [33,34]. In our study, the APACHE II score was also a risk factor to predict mortality in patients with sepsis-induced AKI undergoing CRRT. The APACHE II score was higher in non-survivors than survivors (24.57 ± 5.89 vs. 26.92 ± 5.76, p < .01). It is also an authoritative scoring system for assessing the severity of critical illness, which is also shown in our study. The non-survivors had more frequency of shock than those of survivor. In addition, old age is a well-known predictor of mortality in sepsis patients and in patients receiving CRRT [35,36]. This finding was confirmed in our study in that the survivors were younger than the non-survivors (64 ± 14 years vs. 69 ± 12 years, p < .01). Thrombocytopenia is common in patients receiving CRRT [32,37]. Wu et al. reported that a low platelet count may be associated with hospital mortality in patients treated by CRRT [38]. In the present study, the average platelet count was higher in the survivors than in the non-survivors (178 ± 101 × 10³/µL vs. 134 ± 84 × 10³/µL, p < .01), and a low platelet count was a risk factor to predict mortality. Therefore, in patients with sepsis-induced AKI undergoing CRRT,
caution is recommended when treating older patients and those with a high APACHE II score or a low platelet count.

There are some reports that levels of creatinine at the time of CRRT initiation do not have a negative influence on mortality [39]. Other reports suggest that high creatinine levels at the time of CRRT initiation are associated with better patient survival [40,41]. The latter finding was supported by our study. Serum creatinine levels are dependent upon age, gender, nutritional status, presence of liver disease, and fluid volume status [42,43]. Non-survivors had more liver cirrhosis than survivors in our study. It is possible that non-survivors also had lower serum creatinine levels than survivors in our study because of decreased production due to liver disease and old age in the non-survivor group. Although serum creatinine was not identified as a risk factor, urine output on CRRT initiation did have an important impact in our study [44,45], which was also shown in our study.

Several literatures reported that there is no significant difference in mortality between patients who receive continuous and intermittent renal replacement therapies [46,47]. The Surviving Sepsis Campaign guidelines suggest using CRRT to facilitate fluid balance in hemodynamically unstable septic patient [47]. In our study, the majority of patients are hemodynamically unstable at the time of initiation of RRT. Thus, we chose the CRRT as a RRT in treating septic AKI patients. However, there is no strong evidence that CRRT is superior to intermittent hemodialysis for AKI in septic shock patients. We believe that more studies are needed to clarify this.

Our study had certain limitations. First, this was a retrospective study, and the study population comprised only Asian participants. Second, the number of patients was relatively small. Thus, a large, prospective, randomized, controlled study is needed. Third, our database only contained data about patients who underwent CVVHDF. Fourth, we cannot measure body weight in 20 patients in ICU before starting CRRT because of patient’s condition and limited number of bed scale. In those cases, we estimated body weight using abdominal and thigh circumference [48].

In our study, the 28-day all-cause mortality in sepsis-induced AKI patients undergoing CRRT was 62%. Age, APACHE II score, RDW score, platelet count, serum creatinine level, and a urine output <0.5 mL/kg/h the first day were predictors for the 28-day all-cause mortality in these patients. Therefore, it will be helpful to consider these factors in the future when treating sepsis-induced AKI patients undergoing CRRT.

**Disclosure statement**

The authors report no conflicts of interest.

The results presented in this paper have not been published previously in whole or part, except in abstract form.

**References**

1. Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis. 1998;32:185–207.
2. Mehta RL, Pascual MT, Soroko S. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 2004;66:1613–1621.
3. Fuchs L, Lee J, Novack V, et al. Severity of acute kidney injury and two-year outcomes in critically ill patients. Chest. 2013;144:866–875.
4. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10:R73.
5. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–818.
6. Lins RL, Elseviers MM, Van der Niepen P, et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant. 2009;24:512–518.
7. Allegretti AS, Steele DJ, David-Kasdan JA, et al. Continuous renal replacement therapy outcomes in
acute kidney injury and end-stage renal disease: a cohort study. Crit Care. 2013;17:R109.

[8] Kao CC, Yang JY, Chen L, et al. Factors associated with poor outcomes of continuous renal replacement therapy. PLoS One. 2017;12:e0177759.

[9] Choi SJ, Ha EJ, Jhang WK, et al. Factors associated with mortality in continuous renal replacement therapy for pediatric patients with acute kidney injury. Pediatr Crit Care Med. 2017;18:e56–e61.

[10] Langenberg C, Wan L, Bagshaw SM, et al. Urinary biochemistry in septic acute renal failure. Nephrol Dial Transplant. 2006;21:3389–3397.

[11] Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure. Kidney Int. 2006;69:1996–2002.

[12] Brenner M, Schaer GL, Mallory DL, et al. Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest. 1990;98:170–179.

[13] Alotaibi R, Basu RK, Goldstein SL, et al. Sepsis-associated acute kidney injury. Semin Nephrol. 2015;35:2–11.

[14] Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference. Crit Care Med. 2003;31:1250–1256.

[15] Kidney Disease: Improving Global Outcomes (KDIGO) Acute kidney injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012;81:2–138.

[16] Ricci Z, Polito A, Polito A, et al. The implications and management of septic acute kidney injury. Nat Rev Nephrol. 2011;7:218–225.

[17] Kellum JA, Johnson JP, Kramer D, et al. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med. 1998;26:1995–2000.

[18] Morgera S, Slowinski T, Melzer C, et al. Renal replacement therapy with high-cut-off hemofilter: impact of convection and diffusion on cytokine clearance and protein status. Am J Kidney Dis. 2004;43:444–453.

[19] Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med. 2009;37:803–810.

[20] Zhang P, Yang Y, Lv R, et al. Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transplant. 2012;27:967–973.

[21] Joannes-Boyau O, Honore PM, Perez P, et al. High volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVQUIRE study): a multicenter randomized controlled trial. Intensive Care Med. 2013;39:1533–1546.

[22] Park JT, Lee H, Kee YK, et al. High-dose versus conventional-dose continuous venovenous hemofiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial. Am J Kidney Dis. 2016;68:599–608.

[23] Simel DL, DeLong ER, Feussner JR, et al. Erythrocyte anisocytosis Visual inspection of blood films vs automated analysis of red blood cell distribution width. Arch Intern Med. 1988;148:822–824.

[24] Karnad A, Poskitt TR. The automated complete blood cell count. Use of the red blood cell volume distribution width and mean platelet volume in evaluating anemia and thrombocytopenia. Arch Intern Med. 1985;145:1270–1272.

[25] Allen LA, Felker GM, Mehta MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail. 2010;16:230–238.

[26] Tonelli M, Sacks F, Arnold M, et al. for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation. 2008;117:163–168.

[27] Kim CH, Park JT, Kim EJ, et al. An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock. Crit Care. 2013;17:R282.

[28] Oh HJ, Park JT, Kim JK, et al. Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Nephrol Dial Transplant. 2012;27:589–594.

[29] Okonko DO, Marley SB, Anker SE, et al. Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unknown origin: evidence of an immune basis. Int J Cardiol. 2013;166:664–671.

[30] Ghaffari S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid Redox Signal. 2008;10:1923–1940.

[31] Di Cesare A, Ruggiero F. Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. Perfusion. 2005;20:83–90.

[32] Liu S, Cheng QL, Zhang XY. Application of continuous renal replacement therapy for acute kidney injury in elderly patients. Int J Exp Med. 2015;8:9973–9978.

[33] Chawla LS, Seneff MG, Nelson DR, et al. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol. 2006;2:22–30.

[34] Rhee H, Jung KS, Park JM, et al. Short- and long-term mortality rates of elderly acute kidney injury patients who underwent continuous renal replacement therapy. PLoS One. 2016;11:e0167067.

[35] Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34:15–21.

[36] Guru PK, Singh TD, Akhoundi A, et al. Association of thrombocytopenia and mortality in critically ill patients on continuous renal replacement therapy. Nephron. 2016;133:175–182.

[37] Wu B, Gong D, Xu B, et al. Decreased platelet count in patients receiving continuous veno-venous hemofiltration: a single-center retrospective study. PLoS One. 2014;9:e97286.
kidney injury requiring renal replacement therapy: a retrospective cohort study. Clin Nephrol. 2017; 88:27–32.

[40] Cerda J, Cerda M, Kilcullen P, et al. In severe acute kidney injury, a higher serum creatinine is paradoxically associated with better patient survival. Nephrol Dial Transplant. 2007;22:2781–2784.

[41] da H, Passos R, Ramos JG, et al. A clinical score to predict mortality in septic acute kidney injury patients requiring continuous renal replacement therapy: the HELENICC score. BMC Anesthesiol. 2017;17:21.

[42] Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: part II. Glomerular filtration rate, proteinuria, and other markers. Am Fam Physician. 2004;70:1091–1097.

[43] Beben T, Rifkin DE. GFR estimating equations and liver disease. Adv Chronic Kidney Dis. 2015;22:337–342.

[44] Oh HJ, Shin DH, Lee MJ, et al. Urine output is associated with prognosis in patients with acute kidney injury requiring continuous renal replacement therapy. J Crit Care. 2013;28:379–388.

[45] Lee JH, Kim HY, Bae EH, et al. Biomarkers predicting survival of sepsis patients treated with continuous renal replacement therapy. Chonnam Med J. 2017;53:64–68.

[46] Kellum JA, Angus DC, Johnson JP, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med. 2002; 28:29–37.

[47] Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.

[48] Buckley RG, Stehman CR, Dos Santos FL, et al. Bedside method to estimate actual body weight in the emergency department. J Emerg Med. 2012;42:100–104.

[49] Bagshaw SM, Laupland KB, Boiteau PJ, et al. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care. 2005;20:155–161.